B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+31.47%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$294M
(-9.8%)
Cap. Flow
-$772M
Cap. Flow
% of AUM
-28.57%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
109
New
24
Increased
20
Reduced
34
Closed
23
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphatec Holdings
ATEC
|
+$39.7M |
| 2 |
Humana
HUM
|
+$32.6M |
| 3 |
Maze Therapeutics
MAZE
|
+$29.9M |
| 4 |
Avalo Therapeutics
AVTX
|
+$25.8M |
| 5 |
Alamar Biosciences
ALMR
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$78.9M |
| 2 |
Nuvalent
NUVL
|
+$71.8M |
| 3 |
CG Oncology
CGON
|
+$66.7M |
| 4 |
argenx
ARGX
|
+$55.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$46.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.44% |
| 2 | Miscellaneous | 3.68% |
| 3 | Financials | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Climb Bio
CLYM
$591M
| $36.5M | 1.35% |
2,797,375
+1,267,700
| +83% | +$13.1M |
2026 Q1
1 quarter
|
|
27
CareDx
CDNA
$3.35B
| $34.8M | 1.29% |
1,220,602
-952,544
| -44% | -$20.7M |
2025 Q3
3 quarters
|
|
|
28
Maze Therapeutics
MAZE
$1.46B
| $34M | 1.26% |
+1,140,040
| New | +$29.9M |
2026 Q2
0 quarters
|
|
29
Bright Minds Biosciences
DRUG
$500M
| $34M | 1.26% |
483,822
-55,886
| -10% | -$4.39M |
2025 Q3
3 quarters
|
|
30
Acadia Healthcare
ACHC
$2.95B
| $33.7M | 1.25% |
1,141,477
+495,577
| +77% | +$12.7M |
2026 Q1
1 quarter
|
|
31
Nektar Therapeutics
NKTR
$1.26B
| $33.1M | 1.22% |
473,617
+250,916
| +113% | +$18.4M |
2026 Q1
1 quarter
|
|
32
Corvus Pharmaceuticals
CRVS
$789M
| $31.8M | 1.18% |
2,126,298
+373,500
| +21% | +$5.18M |
2026 Q1
1 quarter
|
|
33
Nurix Therapeutics
NRIX
$2.59B
| $31.2M | 1.15% |
1,286,769
-463,997
| -27% | -$7.9M |
2025 Q4
2 quarters
|
|
34
Inspire Medical Systems
INSP
$1.97B
| $30.2M | 1.12% |
677,570
| – | – |
2023 Q3
11 quarters
|
|
|
35
Avalo Therapeutics
AVTX
$635M
| $30.1M | 1.11% |
+1,629,182
| New | +$25.8M |
2026 Q2
0 quarters
|
|
|
36
Alamar Biosciences
ALMR
$1.76B
| $29.4M | 1.09% |
+1,083,983
| New | +$24.5M |
2026 Q2
0 quarters
|
|
37
Danaher
DHR
$158B
| $28.7M | 1.06% |
150,627
+11,300
| +8% | +$2.05M |
2025 Q1
5 quarters
|
|
38
Intuitive Surgical
ISRG
$148B
| $27.9M | 1.03% |
70,137
-7,160
| -9% | -$3.13M |
2024 Q1
9 quarters
|
|
39
Oruka Therapeutics
ORKA
$5.08B
| $26.5M | 0.98% |
+278,164
| New | +$18.5M |
2026 Q2
0 quarters
|
|
40
Avalyn Pharma
AVLN
$1.05B
| $26.4M | 0.98% |
+801,395
| New | +$23.1M |
2026 Q2
0 quarters
|
|
41
Aveanna Healthcare
AVAH
$2.7B
| $26.3M | 0.97% |
3,065,106
+861,600
| +39% | +$6.07M |
2026 Q1
1 quarter
|
|
42
BioAge Labs
BIOA
$249M
| $25.3M | 0.94% |
1,033,129
-167,458
| -14% | -$3.03M |
2026 Q1
1 quarter
|
|
43
Boston Scientific
BSX
$62.3B
| $25.1M | 0.93% |
587,567
+241,100
| +70% | +$13.1M |
2026 Q1
1 quarter
|
|
44
Vera Therapeutics
VERA
$1.93B
| $24.2M | 0.9% |
564,724
+40,900
| +8% | +$1.52M |
2025 Q3
3 quarters
|
|
45
Repligen
RGEN
$11.3B
| $24.2M | 0.89% |
177,100
+129,600
| +273% | +$15.9M |
2023 Q2
12 quarters
|
|
46
Zura Bio
ZURA
$423M
| $23.5M | 0.87% |
3,980,295
-8,694
| -0.2% | -$41.4K |
2024 Q3
7 quarters
|
|
47
Guardant Health
GH
$21.9B
| $22.2M | 0.82% |
147,850
-351,862
| -70% | -$38.3M |
2026 Q1
1 quarter
|
|
48
Evolus
EOLS
$477M
| $21.9M | 0.81% |
3,155,209
+50,000
| +2% | +$295K |
2025 Q4
2 quarters
|
|
49
Natera
NTRA
$56.9B
| $21.6M | 0.8% |
79,500
-49,500
| -38% | -$10.6M |
2025 Q4
2 quarters
|
|
50
OrthoPediatrics
KIDS
$581M
| $21.1M | 0.78% |
1,100,370
| – | – |
2022 Q4
14 quarters
|
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q2 2026 Portfolio in Review
As of Q2 2026, Braidwell held 109 positions worth $2.7B, down 9.8% from $3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Braidwell withdrew a net $772M in Q2 2026, closing 23 positions and reducing 34 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $78.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Humana worth $45.5M.
- Braidwell's largest Q2 2026 buy was Humana: 114,500 shares worth $45.5M.
- Braidwell added most to Alphatec Holdings in Q2 2026, an estimated $39.7M increase.
- Braidwell's biggest Q2 2026 reduction was argenx, cutting an estimated $55.5M.
- Braidwell fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $78.9M.
- Braidwell's ten largest holdings make up 32% of its $2.7B portfolio in Q2 2026.
- Braidwell opened 24 new positions and closed 23 in Q2 2026.
- Braidwell's portfolio value fell 9.8% quarter-over-quarter to $2.7B.
Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.